FDA approves the first companion Dx for use with multiple NSCLC drugs
The U.S. Food and Drug Administration has approved the Oncomine Dx Target Test from Thermo Fisher Scientific Inc. It is the first test of its kind to screen tumor samples for biomarkers associated with multiple cancer therapies, in this case for non-small-cell lung cancer (NSCLC). It is expected to enable more rapid evaluation of treatment options for these patients, in days rather than over several weeks.
Shares of med-tech firms surge as investors warm to sector, driven by optimism
Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead.
Device deals climb with a focus on cancer, cardiovascular markets
The number of medical device deals and their disclosed values appear to be rising, according to data from Cortellis Deals Intelligence (CDI). CDI reported 202 med-tech deals in 2014, compared with 237 deals in 2015 and 287 deals in 2016. The total value of deals was $22.85 million in 2014, $251.06 million in 2015 and $1.54 billion in 2016.